Aging is the most prominent risk factor for Parkinson's disease. Yet, consensus of how advancing age may predispose the dopamine (DA) system to parkinsonism is lacking. Three age ranges of female rhesus monkeys, 8-9, 15-17, and 21-31 years, received unilateral DA depletion with intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Morphological and biochemical analyses of DAdepleted and intact hemispheres revealed three primary findings: (1) The intact striatum exhibited age-related declines in dopamine (DA) and homovanillic acid (HVA) that were present by middle age; (2) In the MPTP-treated striatum, the compensatory increase in DA activity was absent in old monkeys; and (3) Age-associated morphological changes included declines in the density of tyrosine hydroxylase (TH) positive fibers in striatum, decreased nigral soma size, and optical density of TH, but no significant loss of neurons. These findings suggest that aging produces changes in the nigrostriatal DA system that approach the threshold for expression of parkinsonian features, and that progressive impairment of plasticity may be central to the role of aging in development of parkinsonism.
The mesostriatal dopamine (DA) system exhibits dramatic degenerative changes in Parkinson's disease (PD). The morphological and biochemical patterns of these changes are well characterized and consistent (Fahn, 2003) . Aging is a well-established risk factor for PD (Mayeux et al., 1995; Tanner and Goldman, 1996; Totaro et al., 2005) . In contrast to PD, the pattern of aging-related changes in the DA system varies considerably among species (e.g. Morgan and Finch, 1988) . Even within a species, variability exists in the exact pattern of changes reported and whether age-related changes could be a precursor to the degeneration seen in PD. For nonhuman primates, there tends to be agreement that declines in striatal DA content accompany advancing age, but associated changes in midbrain DA neuron numbers and function are a source of disagreement (GoldmanRakic and Brown, 1981; Irwin et al., 1994; Pakkenberg et al., 1995; Emborg et al., 1998; Gerhardt et al., 2002; McCormack et al., 2004) . In addition, while inclusion of young adult, middleaged, and elderly individuals is considered a proper experimental design for studies of the biology of aging, in reality this can be difficult to accomplish and many reports in the literature compare only two of these age groups. As a consequence, significant gaps exist in our understanding of the development of changes in the DA system over the lifespan in primates. In the present study, we were fortunate to have available for study three age ranges of female rhesus monkeys: 8-9 years (N = 3), 15-17 years (N = 4), and 21-31 years (N = 6). It is documented that rhesus monkeys exhibit aging-related changes consistent with a rate of aging 3:1 as compared to humans (Andersen et al., 1999) . Accordingly, our groups of animals correspond to humans aged 24-27 years, 45-51 years, and 63-93 years. We contend that these correspond to generally held views of young adulthood, middle age, and advanced age. In the present study, we treated monkeys with unilateral intracarotid infusion of the DA neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to create unilateral www.elsevier.com/locate/ynbdi Neurobiology of Disease 26 (2007) 56 -65
